OnKure Therapeutics (NASDAQ:OKUR) Earns Buy Rating from HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 132.96% from the company’s current price.

A number of other analysts have also recently commented on the stock. Oppenheimer began coverage on shares of OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 target price for the company. Lifesci Capital upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, October 10th.

OnKure Therapeutics Stock Performance

NASDAQ OKUR traded down $1.42 during trading on Thursday, hitting $17.17. The company’s stock had a trading volume of 24,811 shares, compared to its average volume of 27,278. OnKure Therapeutics has a fifty-two week low of $9.80 and a fifty-two week high of $86.70. The company has a market cap of $57.35 million, a PE ratio of -1.02 and a beta of 0.21.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.